Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anxo Pharmaceutical CoROCO:6677 +0.88%66 Days Payable is 37.23 as of Dec. 2025, which is 35% below its 10-year median of 57.44. GuruFocus rates ROCO:6677 with a GF Score™ of 66/100 and a GF Value™ of NT$30.26 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 927 Drug Manufacturers companies, Anxo Pharmaceutical Co ranks worse than 81.55% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anxo Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anxo Pharmaceutical Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anxo Pharmaceutical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Anxo Pharmaceutical Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Anxo Pharmaceutical Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anxo Pharmaceutical Co (ROCO:6677) has a Days Payable of 37.23 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Anxo Pharmaceutical Co and its competitors. This is 35% below median its historical median of 57.44. Over the past decade, Anxo Pharmaceutical Co's Days Payable has ranged from 42.31 to 86.74. According to the industry distribution chart, Anxo Pharmaceutical Co ranks #756 out of 927 companies in the Drug Manufacturers industry, placing it in the top 81.6%.
Is Anxo Pharmaceutical Co's Days Payable too high?
Anxo Pharmaceutical Co's current Days Payable of 37.23 is 35% below median its 10-year median of 57.44. Over the past 10 years, this metric has ranged from a low of 42.31 to a high of 86.74. The Drug Manufacturers industry median Days Payable is 90.38. Anxo Pharmaceutical Co's value of 37.23 is 58.8% below this industry median. Based on the distribution chart, Anxo Pharmaceutical Co ranks #756 out of 927 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Anxo Pharmaceutical Co has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Anxo Pharmaceutical Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Anxo Pharmaceutical Co ranks #756 out of 927 companies for Days Payable. This places Anxo Pharmaceutical Co in the lower half of its industry. The industry median Days Payable is 90.38. Anxo Pharmaceutical Co's value of 37.23 is 58.8% below this benchmark. Historically, Anxo Pharmaceutical Co's own Days Payable has ranged from 42.31 to 86.74 over the past decade. While the company's 10-year median is 57.44 vs. the industry median of 90.38, Anxo Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anxo Pharmaceutical Co's current Days Payable of 37.23 is 58.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Anxo Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anxo Pharmaceutical Co's current Days Payable is 37.23, which is 35% below median its own 10-year median of 57.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anxo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Anxo Pharmaceutical Co (ROCO:6677) is currently considered Possible Value Trap. The stock's GF Value™ is NT$30.26, compared to a current price of NT$17.20 — trading 43.2% below its estimated fair value. The current Days Payable is 37.23, which is 35% below median its 10-year median of 57.44 and 58.8% below the Drug Manufacturers industry median of 90.38. Anxo Pharmaceutical Co's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Anxo Pharmaceutical Co (ROCO:6677), the current Days Payable is 37.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anxo Pharmaceutical Co (ROCO:6677) Overvalued in 2026?
Based on GuruFocus' analysis, Anxo Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$17.20 is trading 43.2% below its estimated GF Value™ of NT$30.26.
GuruFocus considers Anxo Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for ROCO:6677:
Days Payable: 37.23 (35% below median its 10-year median of 57.44)
GF Value™: NT$30.26 vs. price of NT$17.20 (43.2% below fair value)
Industry Position: 58.8% below the Drug Manufacturers median (#756 of 927)
No single metric tells the full story. See the ROCO:6677 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.
66GF Score
Get the complete analysis for ROCO:6677
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6677 has been successfully added to your 
